TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14669818
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field in combination with essential oils administered for 26 weeks
Study: 1359666
Drug: Non-sedative antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-sedative antihistamine
Study: 25846070
Drug: Montelukast treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast treatment for 9 months
Study: 25846070
Drug: Routine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine and placebo treatment
Study: 19531445
Drug: Accelerated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated treatment (omitting three cycles of FSH/IUI)
Study: 19531445
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (three cycles of CC/IUI, three cycles of FSH/IUI, up to six cycles of IVF)
Study: 19165198
Drug: Accelerated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated treatment
Study: 18284641
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated SGA controls)
Study: 11862171
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg/d for 12 weeks)
Study: 10550134
Drug: 24-hour paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24-hour paclitaxel infusion
Study: 2314151
Drug: Nalmefene (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (1 mg intravenous)
Study: 7401832
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% lidocaine applied to the carotid bifurcation (12 patients)
Study: 31693275
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg
Study: 31693275
Drug: Intravenous exendin
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous exendin (9-39) 600 pmol/kg/min
Study: 15473615
Drug: Higher-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose remifentanil (0.5 microg kg(‐1)min(‐1))
Study: 15473615
Drug: Lower-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose remifentanil (0.25 microg kg(‐1)min(‐1))
Study: 15473615
Drug: Higher-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose remifentanil
Study: 11479476
Drug: Tezosentan (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (5, 20, 50, and 100 mg over 1 hour each)
Study: 14688860
Drug: Rhesus‐human reassortant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus‐human reassortant rotavirus (RRV‐TV) vaccine
Study: 14688860
Drug: Monthly rates
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly rates of rotavirus-related episodes
Study: 27497519
Drug: Salmon intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon intake (two 150-g portions per week)
Study: 23790990
Drug: State-sponsored program
Approvals — FDA: no, EMA: no, PMDA: no
Description: State-sponsored program with twice-weekly gym classes
Study: 11355917
Drug: Primary prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary prevention by dietary intervention and drugs; specific details not mentioned.
Study: 3061425
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (mean dose 11.5 mg over 3.4 min)
Study: 3061425
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (mean dose 6.0 mg over 3.3 min)
Study: 25605544
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human erythropoietin (rhEPO) 33,000 IU administered at days 1-3
Study: 25605544
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 1,000 mg per day for 3 days + 0.9% normal saline (placebo)
Study: 12452944
Drug: High-dose interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interferon-alpha therapy (daily 9 MU for 4 weeks, then 6 MU for weeks 5-8, 3 MU for weeks 9-12, and 1.5 MU for weeks 13-48) with ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 weeks
Study: 12452944
Drug: Standard-dosage interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dosage interferon-alpha therapy (thrice weekly 6 MU for 12 weeks, then 3 MU for 36 weeks) with ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 weeks
Study: 9605002
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg intravenously, 5 minutes before chemotherapy)
Study: 9605002
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg intravenously, 5 minutes before chemotherapy) with additional doses if vomiting occurs
Study: 8583516
Drug: Enhanced Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Care day treatment program including drug free contingent work therapy and housing
Study: 2666339
Drug: RHEZ6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RHEZ6 regimen (4 drug, 6 months: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide)
Study: 2666339
Drug: RHE9 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RHE9 regimen (3 drug, 9 months: Rifampicin, Isoniazid, Ethambutol)
Study: 140084
Drug: bufexamac cream
Normalized name: bufexamac
DrugBank: Bufexamac (DB13346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bufexamac cream
Study: 25654175
Drug: Active quality
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active quality improvement interventions (nurse specialist, monthly audit-feedback, network educational events, internet blog)
Study: 22480093
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg thrice daily
Study: 19523083
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test in obese children and adolescents
Study: 16733916
Drug: estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol valerate (E2 V) 1 mg/d + medroxyprogesterone acetate (MPA) 2 mg/d
Study: 16733916
Drug: conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conjugated equine estrogen 0.45 mg/d + MPA 2 mg/d
Study: 16733916
Drug: tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibolone 1.25 mg/d
Study: 9150774
Drug: Adenosine infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine infusion, 80 micrograms.kg-1.min-1 during surgery and 40 micrograms.kg-1.min-1 for 3 hours postoperatively
Study: 9150774
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion during surgery
Study: 29889390
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with proton pump inhibitors (PPIs)
Study: 29889390
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with PPI + ursodeoxycholic acid (UDCA)
Study: 24867408
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g bLF daily for 1 year
Study: 24867408
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g bLF daily for 1 year
Study: 24867408
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g bLF daily for 1 year
Study: 20138189
Drug: GM-CSF (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (150 microg) + hepatitis B vaccine (20 microg)
Study: 20138189
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (40 microg) only
Study: 20138189
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (20 microg) each time
Study: 19457618
Drug: Oxytocin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (single dose administered intranasally)
Study: 19457618
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single dose administered intranasally)
Study: 16794364
Drug: lanreotide 30
Normalized name: lanreotide 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanreotide 30 mg
Study: 10845898
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT)
Study: 29887289
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous Oxide (N2O) inhalation (50% for 30 minutes)
Study: 24836523
Drug: Organ-specific dose
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ-specific dose reduction (OSDR) and attenuation-based tube potential selection (ATPS)
Study: 20195613
Drug: Modeling in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modeling in value-based medicine (VBM)
Study: 19173919
Drug: rh-endostatin plus
Normalized name: Endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh-endostatin plus NP chemotherapy
Study: 12051882
Drug: Mitomycin 8
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin 8 mg/m², Doxorubicin 40 mg/m², Cisplatin 60 mg/m² (MAP chemotherapy)
Study: 10063926
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 infusion (30 microg/hr)
Study: 23851069
Drug: Dapagliflozin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin at doses of 0.3mg and above
Study: 23851069
Drug: Dapagliflozin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin at doses of 0.1mg and above
Study: 21415052
Drug: initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: initial combination therapy
Study: 21415052
Drug: initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: initial combination with prednisone
Study: 21415052
Drug: initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: initial combination with infliximab
Study: 19105889
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg vitamin D(2)
Study: 17339864
Drug: dl-Methylphenidate (MPH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-Methylphenidate (MPH) 0.3 mg/kg administered orally 30 min before ethanol (0.6 gm/kg)
Study: 17339864
Drug: dl-Methylphenidate (MPH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-Methylphenidate (MPH) 0.3 mg/kg administered orally 30 min after ethanol (0.6 gm/kg)
Study: 10967897
Drug: nCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP treatment (Group L)
Study: 9366458
Drug: Sufentanil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (3 microg/kg) administered over 2 min
Study: 9366458
Drug: Muscle relaxant
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle relaxant (Pancuronium 0.1 mg/kg) administered after sufentanil
Study: 3460327
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (VP16‐213 with cytosine arabinoside and doxorubicin) (group 2: n = 10)
Study: 30859608
Drug: Apixaban, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban, 2.5 mg x 2/day for 6 months
Study: 25586270
Drug: Restrictive RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive RBC transfusion (Hb < 9.7 g/dL; < 6 mmol/L)
Study: 25586270
Drug: Liberal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal RBC transfusion (Hb < 11.3 g/dL; < 7 mmol/L)
Study: 19372341
Drug: Colloid preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid preload (15 mL/kg hydroxyethyl starch (HES) 130/0.4 [Voluven 6%])
Study: 16583194
Drug: PEG-C preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-C preparation (polyethylene glycol solution plus contrast medium)
Study: 16583194
Drug: PEG preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG preparation (polyethylene glycol solution)
Study: 11489000
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) and Carboplatin (AUC 5)
Study: 11489000
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2 in 3 h) and Carboplatin (AUC 5)
Study: 8041980
Drug: Clonidine 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.005 mg/kg p.o.
Study: 8041980
Drug: Lorazepam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 0.03 mg/kg p.o.
Study: 2656310
Drug: Gestrinone 2.5
Normalized name: gestrinone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 2.5 mg capsules three times weekly orally
Study: 2656310
Drug: Gestrinone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 5.0 mg capsules twice weekly orally
Study: 2656310
Drug: Gestrinone 5
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 5 mg vaginal tablets three times weekly
Study: 2656310
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment for 24 months
Study: 2656310
Drug: Discontinuation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation at 1 year
Study: 16732083
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl (50 microg/kg)
Study: 16732083
Drug: Low-dose fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fentanyl (10 microg/kg)
Study: 15623588
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles (TXT q 3w)
Study: 15623588
Drug: Docetaxel 30
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 30 mg/m2 days 1, 8, 15, 22, and 29 every 6 weeks + prednisone 5 mg twice a day for a total of 5 cycles (TXT qw)
Study: 15623588
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles (MTZ q 3w)
Study: 11717659
Drug: Presumptive sexually
Normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumptive sexually transmitted disease treatment during pregnancy
Study: 9158077
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (Premarin 0.625 mg and Norgestrel 1 mg) for more than 1 year
Study: 8198022
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg/day plus bezafibrate 400 mg/day
Study: 8198022
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/day plus bezafibrate 400 mg/day
Study: 8198022
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/day plus cholestyramine 8 g/day
Study: 3294021
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg daily
Study: 3294021
Drug: Verapamil 160
Normalized name: verapamil 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 160 mg twice daily + Bendrofluazide 5 mg daily
Study: 3294021
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg daily + Verapamil 160 mg twice daily
Study: 31719072
Drug: Cannabis-based medicine
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration, treated for 6 months.
Study: 31719072
Drug: Cannabis-based medicine
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis-based medicine extract (CBME)
Study: 12598435
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and prophylactic treatment (measurement of anterior chamber depth and intraocular pressure, followed by laser iridotomy for those with occludable angles)
Study: 7552933
Drug: Loratadine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine, 20 mg once daily for 4 weeks
Study: 1664832
Drug: Temafloxacin 600
Normalized name: temafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 600 mg once daily
Study: 7194172
Drug: Triphasic formulation
Normalized name: Tribasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic formulation (ethinyl oestradiol and levonorgestrel)
Study: 23130817
Drug: Vitamin BC
Normalized name: Vitamin Bc
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin BC capsules plus corresponding deficient hematinics (for groups I, II, III, IV)
Study: 23130817
Drug: Vitamin BC
Normalized name: Vitamin Bc
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin BC capsules only (for group V)
Study: 15569851
Drug: NT-proBNP >
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP > 50 pmol/L and CRP > 0.84 mg/L
Study: 10369709
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (20 g free glutamine replacing 3.8 g of total nitrogen)
Study: 8763084
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine injected into the buttock or internal aspect of the thigh
Study: 8763084
Drug: Inactivated whole-virus
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole-virus vaccine
Study: 1868502
Drug: Captopril (37.5-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (37.5-75 mg/day)
Study: 1868502
Drug: Ibopamine (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (150-300 mg/day)
Study: 28975718
Drug: Febuxostat 40
Normalized name: febuxostat 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 40 mg (increased to 80 mg if serum UA level was ≥6.0 mg/dl on day 14)
Study: 19221871
Drug: Community-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based treatment (COMM)
Study: 19221871
Drug: Clinic-based treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based treatment (CLINIC)
Study: 17451369
Drug: Teriparatide treatment
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide treatment
Study: 7698050
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human recombinant basic fibroblast growth factor (bFGF) applied daily for 6 weeks, then twice a week for 12 weeks
Study: 7698050
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied daily for 6 weeks, then twice a week for 12 weeks
Study: 27530106
Drug: Directives on
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directives on opioid prescribing released by the Veterans Health Administration (VHA) or the Food and Drug Administration (FDA)
Study: 25992918
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone (15 mg/d)
Study: 25992918
Drug: Medium-dose prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose prednisone (30 mg/d)
Study: 25992918
Drug: High-dose prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisone (60 mg/d)
Study: 19565728
Drug: Compound PuHuang
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound PuHuang Granules
Study: 19565728
Drug: NaoXueShuan Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaoXueShuan Tablets
Study: 1437435
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (0.15 mg/kg per dose) and ipratropium bromide (250 micrograms per dose)
Study: 1437435
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol and normal saline (placebo)
Study: 26646751
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of hydrocortisone (0.4‐0.6 mg/kg body weight/day)
Study: 18355797
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy (NPWT) using the Vacuum-Assisted Closure (V.A.C.) system
Study: 18355797
Drug: Standard moist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard moist wound therapy (MWT)
Study: 16043008
Drug: Participants taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants taking prescribed medications
Study: 12390105
Drug: Dextromethorphan 10
Normalized name: DEXTROMETHORPHAN 10MG CHEWABLE TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 10 mg
Study: 7800005
Drug: Antibacterial treatment
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial treatment (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, each given orally four times a day for one week)
Study: 7800005
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg orally per day for four weeks)